<description>&lt;p&gt;Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents.&lt;br /&gt; &lt;br /&gt; &lt;strong&gt;Related Content:&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;a class="related-article" href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.27022?utm_source=podcast_platforms&amp;utm_medium=referral&amp;utm_campaign=related_article_links" target="_blank" rel="noopener"&gt;Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years&lt;/a&gt;&lt;/li&gt; &lt;/ul&gt;</description>

Coronavirus (COVID-19) Q&A

JAMA Network

Evaluating the Effectiveness of Bivalent COVID-19 Vaccines in Children and Adolescents

FEB 6, 202412 MIN
Coronavirus (COVID-19) Q&A

Evaluating the Effectiveness of Bivalent COVID-19 Vaccines in Children and Adolescents

FEB 6, 202412 MIN

Description

Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents. Related Content: